Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Solid Phase Fragment Synthesis of Thymosin α1

A synthetic method and technology of thymosin, which is applied in the field of solid-phase fragment synthesis of thymosin α1, can solve the problems of complex preparation process of pseudoproline dipeptide, difficulty in large-scale preparation, and high price, and achieve low cost and reduced production The effect of shortening the cost and production cycle

Active Publication Date: 2018-10-26
苏州天马医药集团天吉生物制药有限公司
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

thymosin alpha 1 The 1, 8, and 9 positions of the sequence contain 3 Ser, and the 6, 12, and 13 positions contain 3 Thr. Compared with the classic Fmoc / tBu stepwise condensation process, this method can increase thymosin α to a certain extent. 1 Synthetic quality, but thymosin alpha 1 The most difficult sequence interval to synthesize (Lys 17 to Glu 24 The sequence between them can form a ~ helical structure) does not contain Thr or Ser, and the preparation process of Thr or Ser pseudoproline dipeptide is complicated and expensive
Therefore, it is difficult to use this process to prepare cost-competitive high-quality adenosin α on a large scale 1 API

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Solid Phase Fragment Synthesis of Thymosin α1
  • Solid Phase Fragment Synthesis of Thymosin α1
  • Solid Phase Fragment Synthesis of Thymosin α1

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] According to the "fragment Ac(1-4) + stepwise condensation of 5-14 amino acids + Fmoc (15-22) + (23-28)-Wang Resin" synthesis strategy to synthesize the three required fragments, the process flow chart is as follows:

[0048] Ⅰ. Preparation (23-28) - Wang Resin

[0049]

[0050] Ⅱ. Preparation of Fragment Fmoc(15~22) Fully Protected Crude Peptide

[0051]

[0052] Ⅲ. Condensation of fragment Fmoc (15~22) fully protected crude peptide and (23~28)-Wang Resin, and gradually condense to the fifth amino acid

[0053]

[0054] Ⅳ. Preparation of Fragment Ac(1~4) Fully Protected Crude Peptide

[0055]

[0056] Ⅴ. Fragment Ac(1~4) fully protected crude peptide is condensed with (5~28)-Wang Resin, and cracked into crude peptide

[0057]

[0058] Ⅵ. Purification and desalting of crude peptide

[0059]

[0060] (1) Synthesis of fully protected peptide resin of C-terminal fragment A (AA23-AA28) H-Val-Glu(OtBu)-Glu(OtBu)-Ala-Glu(OtBu)-Asn(Trt)-Wang Resin

[0061...

Embodiment 2

[0096] (1) Four fragments were synthesized according to the synthesis strategy of "fragment Ac(1~2)+ stepwise condensation of amino acids at positions 3~14+Fmoc(15~24)+(25~28)-WangResin". The process flow chart is as follows:

[0097] Ⅰ. Preparation (25~28)-Wang Resin

[0098]

[0099] Ⅱ. Preparation of Fmoc(15~24) Fully Protected Crude Peptide

[0100]

[0101] Ⅲ. Condensation of fragment Fmoc (15~24) fully protected crude peptide and (25~28)-Wang Resin, and gradually condense to the third amino acid

[0102]

[0103] Ⅳ. Preparation of Fragment Ac(1~2) Fully Protected Crude Peptide

[0104]

[0105] Ⅴ. Condensation of fragment Ac(1~2) fully protected crude peptide with (3~28)-Wang Resin, and cleavage into crude peptide

[0106]

[0107] Ⅵ. Purification and desalting of crude peptide

[0108]

[0109] The specific operation is as follows:

[0110] a. Synthetic Fragment (25~28)-Wang Resin: Weigh 920.0g Wang Resin (1.2mmol / g) into a 10L reactor, add an appr...

Embodiment 3

[0126] (1) Synthesize the three required fragments according to the synthetic strategy of "Ac+ Fmoc(1~4)+ stepwise condensation of amino acids at positions 5~14+Fmoc(15~22)+(23~28)-WangResin". The process flow chart is as follows :

[0127] Ⅰ. Preparation (23~28)-Wang Resin

[0128]

[0129] Ⅱ. Preparation of Fragment Fmoc(15~22) Fully Protected Crude Peptide

[0130]

[0131] Ⅲ. Condensation of fragment Fmoc (15~22) fully protected crude peptide and (23~28)-Wang Resin, and gradually condense to the fifth amino acid

[0132]

[0133] Ⅳ. Preparation of Fragment Fmoc(1~4) Fully Protected Crude Peptide

[0134]

[0135] Ⅴ. Fragment Fmoc(1~4) fully protected crude peptide is condensed with (5~28)-Wang Resin, acetylated and cracked into crude peptide

[0136]

[0137] Ⅵ. Purification and desalting of crude peptide

[0138]

[0139] The specific operation is as follows:

[0140] a. Synthesis of (23~28)-Wang Resin: Weigh 1100.0g Wang Resin (1.0mmol / g) into a 10L ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
purityaaaaaaaaaa
Login to View More

Abstract

The invention discloses a synthesis technology of thymosin alpha1, which comprises the following steps: synthesizing multiple segments according to the difficult-synthesis sequence of thymosin alpha1, wherein a solid-phase segment condensation method is adopted for the area of difficult sequences so as to improve the synthesis quality and shorten the synthesis time, and a conventional step-by-step condensation method is adopted for the area of easy-synthesis sequences; obtaining all-protected thymosin alpha1 peptide resin on Wang Resin; cracking the peptide resin to obtain crude peptide by taking TFA / m-cresol or TFA / thioanisole / EDT / anisole as a cracking reagent; dissolving the crude peptide and filtering; and performing preparative reversed phase HPLC purification, desalting, rotary evaporation and freeze drying to obtain a finished product of thymosin alpha1 of which the purity can exceed 99%. According to the technology disclosed by the invention, the purity of the synthesized crude peptide can reach about 80%, the purification is easy, and the total yield can reach 30%. The total yield and product quality of thymosin alpha1 produced by the method disclosed by the invention are both much remarkably improved than those of other methods reported in documents; and moreover, the production cycle can be shortened by 40-50%, the production cost is reduced, and the method is suitable for large-scale preparation of high-purity thymosin alpha1.

Description

technical field [0001] The invention relates to the field of chemical synthesis of polypeptide drugs, in particular to a method for synthesizing solid-phase fragments of thymosin α1. Background technique [0002] thymosin a 1 It is an important polypeptide immunoregulatory factor secreted by the thymus, which can significantly enhance immune function, and is recognized as the most effective drug for specifically regulating immune imbalance and enhancing immunity. thymosin a 1 Originally extracted from calf thymus. thymosin a 1 It consists of 28 amino acid residues, with a molecular weight of 3108, an isoelectric point of 4.2, and an acetylated structure at the N-terminal. thymosin a 1 Promote the maturation of T lymphocytes by stimulating peripheral blood lymphocyte mitogens, increase the levels of interferon α, interferon γ, interleukin 2, interleukin 3 and other lymphokines secreted by T cells after antigen or mitogen activation, and increase T cells Surface lymphoki...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K14/575C07K1/06C07K1/04
CPCY02P20/55
Inventor 王良友孙锋高鲁陈逸民夏丹黄保胜
Owner 苏州天马医药集团天吉生物制药有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products